View Clinical Trial (Medical Research Study)
A Phase II Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia - NCT00777036-98105(Clinical Trial 248661)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Seattle |
|
State:
|
|
WA |
| Zip Code: |
|
98105 |
| Conditions: |
|
Leukemia |
| Purpose: |
|
The purpose of this study is to find out if dasatinib is effective in children and
adolescents with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who
prove resistant or intolerant to imatinib or relapsed after imatinib. The side effects this
oral investigational drug may have in children and adolescents will also be studied
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Ph+ CML in chronic, accelerated or blast phase or Ph+ ALL with imatinib-resistant
disease or intolerance
- Lansky or Karnofsky scale > 50
- Life expectancy >= 12 weeks
- Adequate hepatic renal function
Exclusion Criteria:
- Eligibility for potentially-curative therapy including hematopoietic stem-cell
transplantation
- Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal
disease)
- Isolated extramedullary disease
- Prior therapy with dasatinib |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 1, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|